"Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market last week when it introduced a cheap, compounded version of Novo Nordisk's new Wegovy pill. It was an audacious attempt for a piece of the lucrative GLP-1 market that came to a swift and disastrous end the company pulled its product just two days after its launch"
"Regulatory authorities allow for so-called compounded versions of medicines that are in shortage and Wegovy and Zepbound were in shortage following their approvals for weight loss in 2021 and 2023, respectively. A gray market took off, with telehealth companies, online pharmacies and wellness spas offering knockoff versions of the products. Companies finally got their manufacturing acts together, and the shortage has been officially over for more than a year for Zepbound, and nearly a year for Wegovy."
Hims & Hers introduced a cheap compounded version of Novo Nordisk's Wegovy pill and pulled it after regulators vowed action; Novo sued Hims. The FDA is increasing enforcement against unregulated compounded GLP-1 products. Regulatory allowances for compounded medicines during shortages enabled a gray market when Wegovy and Zepbound faced supply constraints after weight-loss approvals in 2021 and 2023. Telehealth companies, online pharmacies and wellness spas offered knockoffs. Manufacturing improved and official shortages ended over a year ago for Zepbound and nearly a year ago for Wegovy, yet compounded products continued to circulate. Compounded drugs are not FDA-approved generics and lack guaranteed equivalence, safety or efficacy.
Read at www.mercurynews.com
Unable to calculate read time
Collection
[
|
...
]